In addition, the two latest clinical trials, the RTOG 0525 and the Nordic trial (NOA-08), suggest that methylation of MGMT promoter also helps to distinguish the response of older GBM patients for chemotherapy with alkylating agent and radiotherapy. The gene discussed is MGMT; the disease is glioblastoma.